Tecentriq + Avastin combination demonstrates improvement in OS, PFS in HCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III IMbrave150 study evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) demonstrated statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with sorafenib in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login